Exact Sciences upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler analyst David Westenberg upgraded Exact Sciences to Overweight from Neutral with an unchanged price target of $90. With strong Cologuard growth and a “clear path” to five years growth rates of above 10%, the 36% pullback in shares since the highs in July “represent a pretty compelling entry point,” the analyst tells investors in a research note. The firm thinks Exact will be only “lightly impacted” by macroeconomic factors or from regulatory factors.